ストックスクリーナーアプリを入手
3.78
10.64%
-0.45
前日終値:
$4.23
開ける：
$4.2
24時間の取引高:
6.65M
Relative Volume:
2.24
時価総額：
$682.73M
収益：
$4.63M
当期純損益:
$-201.14M
株価収益率:
-2.7509
EPS:
-1.3741
ネットキャッシュフロー:
$-167.10M
1週間 パフォーマンス:
-2.33%
1か月 パフォーマンス:
+39.48%
6か月 パフォーマンス:
-4.06%
1年 パフォーマンス:
-19.40%
1日の値動き範囲:
$3.62
$4.265
1週間の範囲:
$3.62
$4.825
52週間の値動き範囲:
$2.67
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.78 | 682.73M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 開始されました | Oppenheimer | Outperform |
| 2025-05-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-05-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-20 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2024-04-22 | 開始されました | Chardan Capital Markets | Buy |
| 2024-04-08 | 開始されました | TD Cowen | Buy |
| 2024-04-03 | 開始されました | Wedbush | Outperform |
| 2024-01-16 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-10-09 | 開始されました | BMO Capital Markets | Outperform |
| 2023-07-31 | 開始されました | Guggenheim | Buy |
| 2023-04-18 | 開始されました | Stifel | Buy |
| 2022-11-14 | 開始されました | Goldman | Neutral |
| 2022-11-14 | 開始されました | JP Morgan | Overweight |
| 2022-11-14 | 開始されました | Jefferies | Buy |
| 2022-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prime Medicine Inc (PRME) 最新ニュース
Prime Medicine Stock Dips As Traders Weigh Heavy Losses - timothysykes.com
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
H.C. Wainwright reiterates Prime Medicine stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine wins arbitration to advance gene editing program, shares jump over 15%. - Pluang
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
Prime Medicine stock surges after winning arbitration with Beam - Investing.com
Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win - Investing.com India
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute - Moomoo
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Canada
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
Prime Medicine, Inc. Files Form 8-K With SEC – Company Details, Stock Info, and Compliance Highlights - Minichart
Prime Medicine Stock Pops As ARK, Analysts Back Gene Editor - StocksToTrade
Prime Medicine wins arbitration over AATD therapy PM647 - Investing.com
Prime Medicine wins arbitration over AATD therapy PM647 By Investing.com - Investing.com India
Prime Medicine wins arbitration ruling, PM647 found within its field; Beam's claims denied - TradingView
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
Prime Medicine clears Beam dispute, keeps PM647 for AATD - Stock Titan
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Yahoo Finance
Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” - Yahoo Finance
10 Overlooked Penny Stocks to Buy Right Now - Insider Monkey
PRMEPrime Medicine Inc Options - Finviz
Enterprise value to revenue forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
PRME Q1 2026 Earnings: EPS Misses Estimates but Stock Gains on Pipeline ProgressEarnings Decline Risk - dars.gov.et
Enterprise value to EBIT forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2500 Growth Benchmark - marketscreener.com
Price to book forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Price to sales forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
H.C. Wainwright upgrades Prime Medicine stock rating to buy By Investing.com - Investing.com Nigeria
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Microcap Growth Benchmark Index - marketscreener.com
H.C. Wainwright upgrades Prime Medicine stock rating to buy - Investing.com
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 2000 Growth Benchmark - marketscreener.com
H.C. Wainwright Upgrades Prime Medicine(PRME.US) to Buy Rating, Announces Target Price $8 - Moomoo
Prime Medicine, Inc.(NasdaqGM: PRME) added to Russell 3000E Growth Benchmark - marketscreener.com
Prime Medicine, Inc.(NasdaqGM:PRME) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
PRME Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Gene Editing PipelineFinancial Health Score - dars.gov.et
Prime Medicine, Inc. Actuals & Estimates (NASDAQ:PRME) - TradingView
Prime Medicine Inc (PRME) 財務データ
収益
当期純利益
現金流量
EPS
Prime Medicine Inc (PRME) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
2.64%
大文字化:
|
ボリューム (24 時間):